


[摘要] 目的 祛萎健胃湯治療慢性萎縮性胃炎伴癌前病變的療效。方法 隨機收集120例于2011年5月—2015年5月在福州市中醫院脾胃病專科門診治療的患者,隨機分為治療組與對照組,每組60例,對照組予摩羅丹進行治療;治療組口服祛萎健胃湯進行治療。兩組患者臨床療效、中醫癥狀輕重分級、以及胃黏膜病理積分差異進行對比。 結果 治療組總有效率90.0%優于對照組71.7%(P<0.01);治療組經治療后胃黏膜萎縮積分為(2.5±1.3)分,腸上皮化生積分為(1.5±0.7)分,異型增生積分為(1.3±0.7)分,差異有統計學意義(P<0.05)。結論 祛萎健胃湯治療CAG伴癌前病變能明顯改善臨床癥狀,逆轉胃黏膜病理改變。
[關鍵詞] 慢性萎縮性胃炎;癌前病變;祛萎健胃湯
[中圖分類號] R246.1 [文獻標識碼] A [文章編號] 1674-0742(2016)10(b)-0185-03
[Abstract] Objective To analyze the curative effects of chronic atrophic gastritis with precancerous lesions treated with Quweijianwei Decoction. Methods Random collected 120 cases had in May 2011 to May 2015 in Fuzhou City Hospital of traditional Chinese medicine spleen stomach specialist outpatient treatment of patients randomly divided into treatment group and control group, 60 cases in each group, patients in control group were treated with Rama Dan treatment; treatment group were treated with removing wilt Jianwei Decoction treatment. The clinical efficacy of the two groups of patients, TCM symptoms and grade, as well as gastric mucosal pathological score differences were compared. Results The treatment group the total efficiency was 90% better than the control group 71.7%(P < 0.01); treatment group after treatment of gastric mucosa atrophy score was (2.5±1.3)points, intestinal epithelium of students score (1.5 ± 0.7)points, dysplasia points to(1.3± 0.7)points were significantly lower than the control group(P < 0.05). Conclusion The implementation of Quweijianwei Decoction for CAG with precancerous lesions can significantly improve the clinical symptoms, reverse the pathological changes of gastric mucosa.
[Key words] Chronic atrophic gastritis; Precancerous lesion; Quweijianwei Decoction
慢性萎縮性胃炎(chronic gastritis,CAG),主要是由胃黏膜固有腺體萎縮而造成黏膜變薄,或者是伴有Dys(異型增生)和IM(腸上皮化生)等病理特點而引起的一種常見病[1-5]。為了減少胃癌的發生和逆轉胃癌前病變或阻斷病變的進展,筆者采用祛萎和胃湯治療120例2011年5月—2015年5月的福州市中醫院脾胃病專科門診慢性萎縮性胃炎患者,現報道如下。
1 資料與方法
1.1 一般資料
隨機收集120例曾于福州市中醫院脾胃病專科門診患者,以隨機數學表法將其分為治療組和觀察組(各60例)。治療組中男33例、女27例;年齡平均(43.12±10.36)歲,病程平均(4.29±1.37)年;對照組中男32例、女28例,平均年齡(42.32±11.16)歲,平均(4.35±1.13)年。兩組患者一般資料差異無統計學意義,P>0.05。
2 方法
2.1 治療方法
對照組給予摩羅丹(濃縮丸)(主要成分:百合、茯苓、玄參、烏藥、澤瀉、麥冬、當歸、茵陳、元胡、白芍、石斛、九節菖蒲、川芎、雞內金等藥物;……